Our work demonstrates the functional importance of the m6A methylation and its modulator, and uncovers a critical FTO‐PGC‐1α axis for developing effective therapeutic strategies in the treatment of ccRCC. The gene discussed is PPARGC1A; the disease is nonpapillary renal cell carcinoma.